Aqualitas has received a European Union Good Manufacturing Practices (EU-GMP) Certification issued by Beizirksregierung Köln (District of Cologne, Germany) and a Drug Establishment License (DEL) issued by Health Canada in accordance with the Food and Drugs Act.
Myrna L. Gillis, CEO of Aqualitas, states, "this significant milestone reflects our commitment to excellence in manufacturing cannabis products, ensuring exacting attention to produce clean, consistent, and safe products without irradiation while utilizing organic and sustainable processes. Our commitment to pure wellness has been elevated by these important certifications and expands our existing footprint in important global markets."
"The successful attainment of EU-GMP Certification reflects the extraordinary efforts of our quality and operations teams in their persistent and patient pursuit of this important goal," noted Danielle Maitland, Director of Science and Cultivation Technology, who, along with Dorothy Easy, Quality Assurance Person, and Nicholas Vorauer, Lead Extraction Scientist, spearheaded the EU-GMP and DEL compliance initiatives.
The EU-GMP Certification adds to Aqualitas' suite of production certifications, which include IMC-Good Agricultural Practices (IMC-GAP), GAcP, and Clean Green Certifiied® status. This further differentiates Aqualitas® products from other Canadian cannabis licensed producers and will also allow the execution of existing strategic distribution partnerships in Australia and expansion into the UK and Germany, where they anticipate launching the product later this month. It will also expand their research collaborations and support their drug master file for projects in the USA.
For more information:
Aqualitas
www.aqualitas.ca